3 years ago

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French–Spanish experience

Sara Lemoinne, Albert Pares, Anna Reig, Karima Ben Belkacem, Astrid Donald Kemgang Fankem, Farid Gaouar, Raoul Poupon, Chantal Housset, Christophe Corpechot, Olivier Chazouillères

Publication date: Available online 9 August 2018

Source: Clinics and Research in Hepatology and Gastroenterology

Author(s): Sara Lemoinne, Albert Pares, Anna Reig, Karima Ben Belkacem, Astrid Donald Kemgang Fankem, Farid Gaouar, Raoul Poupon, Chantal Housset, Christophe Corpechot, Olivier Chazouillères

Summary
Background & aims

In patients with primary sclerosing cholangitis (PSC), ursodeoxycholic acid (UDCA) treatment improves serum liver tests and surrogate markers of prognosis but has no proven effect on survival. Additional therapies are obviously needed. Fibrates, PPAR agonists with anti-cholestatic properties, have a beneficial effect in primary biliary cholangitis. The aim of this study was to evaluate the safety and efficacy of fibrates in PSC patients.

Methods

Retrospectively, we investigated PSC patients treated with fibrates (fenofibrate 200 mg/day or bezafibrate 400 mg/day) for at least 6 months in addition to UDCA, after an incomplete biochemical response (alkaline phosphatase [ALP] ≥ 1.5 × upper limit of normal) to UDCA. Changes in biochemical parameters and clinical features were assessed.

Results

Twenty patients were included (fourteen from Paris and six from Barcelona): median age 43.8 years, median liver stiffness 11 kPa (≥ F3). Upon treatment with fibrates (median duration of 1.56 years), liver tests significantly improved, including a reduction of ALP levels by 41% and pruritus significantly decreased. No serious adverse event attributable to fibrates occurred. Discontinuation of fibrates was followed by a clear rebound of ALP. Despite biochemical improvement, liver stiffness significantly increased.

Conclusions

Combining UDCA with fibrates results in a significant biochemical improvement and pruritus decrease in PSC patients with incomplete response to UDCA. These results provide a rationale for larger and prospectively designed studies to establish the efficacy and safety of fibrates in PSC.

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.